Related Experiment Video

Updated: May 10, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.5K

Pharmacodynamic biomarkers responsive to mutant huntingtin lowering in a Huntington's disease mouse model

Deanna M Marchionini1, Stef De Lombaerde2, Joëlle van Rijswijk3

  • 1CHDI Management, Inc., The Company That Manages the Scientific Activities of CHDI Foundation, Inc., 350 7(th) Ave, Suite 200, New York, NY, 10001, USA.

Neurobiology of Disease
|April 9, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.1K
Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

2.4K

Related Experiment Videos

Last Updated: May 10, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.5K
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.1K
Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

2.4K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

Articles linked to this work by shared authors, journal, and citation graph.

Development and preclinical evaluation of selective vinyl sulfone-based probes for PET imaging of tumor-associated cathepsins.

EJNMMI radiopharmacy and chemistry·2026

Mapping brain volume changes in the zQ175DN mouse model of Huntington's disease: a longitudinal MRI study.

Biomarker research·2026

Blocking somatic repeat expansion and lowering huntingtin by RNAi synergize to attenuate Huntington's disease pathogenesis in mice.

Science translational medicine·2026

Image-derived input functions for [18F]LW223 and [18F]SynVesT-1 PET in the rodent determined using an autoencoder (IDIF-AE).

Physics in medicine and biology·2026

Accurate Reference Region Calculation in Mouse Brain [18F]fallypride Studies.

Molecular imaging and biology·2026

Comparing kinetic profiles of SV2A radiotracers [18F]SynVesT-1 and [18F]UCB-J using PET imaging in mice.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026

Escalating demand for learning during adolescence impairs social interaction by hyperactivating midbrain dopamine neurons in young adulthood male mice.

Neurobiology of disease·2026

Matrix metalloproteinase-9 is associated with CX3CL1 on tau and amyloid biomarker pathways in APOE4 carriers.

Neurobiology of disease·2026

Genome-wide CRISPRi screen in human iNeurons identifies novel negative mTOR regulator genes associated with focal cortical dysplasia.

Neurobiology of disease·2026

Motor coordination and behavioural deficits in a mouse model of KMT2B-related dystonia.

Neurobiology of disease·2026

Potentiated angiotensin AT1 receptor activity is associated with age-dependent expansion of adrenal-projecting presympathetic circuitry in hypertension.

Neurobiology of disease·2026

Astrocyte-derived extracellular vesicle phosphorylated TDP-43 as a blood-based biomarker for amyotrophic lateral sclerosis.

Neurobiology of disease·2026

A case of tic improvement following tipepidine administration in a boy with Tourette syndrome comorbid with attention-deficit/hyperactivity disorder and autism spectrum disorder.

PCN reports : psychiatry and clinical neurosciences·2026

Subcutaneous MG1113 in severe hemophilia A and B: phase 1b study for safety, pharmacokinetics, and pharmacodynamics.

Research and practice in thrombosis and haemostasis·2026

Efficacy and safety of different TPO-RAs combined with cyclosporine in the treatment of NSAA.

Therapeutic advances in hematology·2026

Mesenchymal Stem Cell-Derived Extracellular Vesicles Ameliorate NaIO3-Induced Dry AMD by Delivering miR-486-3p to Inhibit Lipocalin-2-Mediated Ferroptosis.

MedComm·2026

Effectiveness and safety of telitacicept in refractory ocular myasthenia gravis: a retrospective, real-world study.

Frontiers in immunology·2026

Agomelatine as augmentation therapy with second-generation antipsychotics for negative symptoms of schizophrenia: An open-label randomised clinical trial and electroencephalogram-derived model for treatment response prediction.

General psychiatry·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us